Drugs / Radioactive iodine
Radioactive iodine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04892303 | Mar 2021 → Dec 2027 expected | differentiated thyroid carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT05142904 | Nov 2021 → Nov 2024 | hyperthyroidism, thyroid hormone metabolism, abnormal | Rijnstate Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00115895 | Jan 2000 → Oct 2004 | thyroid tumor | University of Helsinki | Unknown | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT00430547 | Aug 2003 → Jan 2006 | disease of orbital part of eye adnexa | Barwon Health | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | radioactive iodine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04892303 ↗ |
| Known as | (131)I | “Adult subjects (n = 160) diagnosed with papillary or follicular thyroid carcinoma were randomly allocated to receive either 1100 MBq (30 mCi) or 3700 MBq (100 mCi) activity of...” PMID 18382668 ↗ Apr 20081“radioactive iodine (RAI, 131-I)” NCT04892303 ↗ |
| Known as | I131 | “Carbimazole, radio-active iodine (I131)” NCT00430547 ↗ |
| Known as | RAI | “radioactive iodine (RAI)” NCT04892303 ↗ |
| Modality | Other / unclassified | “Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq” NCT00115895 ↗ |
| Route | Oral | “Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq” NCT00115895 ↗ |